PDT Partners LLC Acquires 23,063 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• PDT Partners LLC increased its stake in Halozyme Therapeutics Inc. by 27.4% during the first quarter, acquiring an additional 23,063 shares for a total of 107,125 shares valued at approximately $6.8 million.
• Halozyme reported a quarterly earnings per share (EPS) of $1.54, surpassing analysts' expectations of $1.23, and also announced a revenue of $325.72 million, well above the expected $282.66 million.
• Halozyme's stock has garnered mixed ratings, with four analysts recommending Buy, five Hold, and two Sell, resulting in a consensus target price of $67.11.

PDT Partners LLC increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 27.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,125 shares of the biopharmaceutical company's stock after purchasing an additional 23,063 shares during the period. Halozyme Therapeutics makes up approximately 0.5% of PDT Partners LLC's holdings, making the stock its 22nd biggest position. PDT Partners LLC owned 0.09% of Halozyme Therapeutics worth $6,836,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Penserra Capital Management LLC purchased a new position in Halozyme Therapeutics in the first quarter worth about $125,000. Bessemer Group Inc. increased its position in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 207 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after acquiring an additional 524,802 shares during the last quarter. Fifth Third Bancorp lifted its position in Halozyme Therapeutics by 29.4% in the 1st quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after acquiring an additional 2,276 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Halozyme Therapeutics by 199.0% in the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after acquiring an additional 1,865 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded down $1.42 on Thursday, hitting $73.40. 2,759,569 shares of the stock traded hands, compared to its average volume of 1,975,768. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $75.46. The firm has a 50 day simple moving average of $62.35 and a two-hundred day simple moving average of $59.69. The firm has a market cap of $8.59 billion, a price-to-earnings ratio of 16.80, a PEG ratio of 0.42 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of research analyst reports. Zacks Research raised Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday. Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Leerink Partnrs cut shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. HC Wainwright increased their price target on Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Finally, JPMorgan Chase & Co. lifted their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $67.11.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $46,598,493.69. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director directly owned 46,952 shares of the company's stock, valued at $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 104,000 shares of company stock worth $6,316,120 in the last three months. Insiders own 2.90% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.